Optometry & Vision Science:
Feature Article on Line
Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and Opinion of Contact Lens Performance
Chalmers, Robin L.; Begley, Carolyn G.; Moody, Kurt; Hickson-Curran, Sheila B.
†OD, MS, FAAO
‡BSc(Hons), MCOptom, FAAO
Clinical Trial Consultant, Atlanta, Georgia (RLC), Indiana University School of Optometry, Bloomington, Indiana (CGB), and Johnson & Johnson Vision Care, Inc., Jacksonville, Florida (KM, SBH-C).
Received March 5, 2012; accepted June 6, 2012.
Robin L. Chalmers Clinical Trial Consultant 2097 East Lake Road Atlanta, Georgia 30307 e-mail: Chalmers2097@gmail.com
Purpose. To report on the development and validation of a short form of the Contact Lens Dry Eye Questionnaire (the CLDEQ-8) to enable it to reflect status of and change in overall opinion (“opinion”) of soft contact lenses (SCLs).
Methods. Item reduction for the CLDEQ was achieved by correlation with overall opinion of SCLs at follow-up visits in a sample of 38 SCL wearers at one academic clinical site. The CLDEQ-8 score (frequency plus late day intensity of dryness, discomfort, and “blurry vision”; frequency of “closing eyes to rest them” and “removing CLs to relieve discomfort”) was then tested in 379 SCL wearers in a multicenter study with analysis stratified by opinion ratings at baseline and 2 weeks postrandomization to new silicone hydrogel SCLs. The sum of CLDEQ-8 scores (maximum 37) was correlated with opinion by Spearman's rank correlation coefficient and analyzed for change in opinion by analysis of variance (ANOVA).
Results. The CLDEQ-8 scores in the validation sample were highly correlated with habitual baseline opinion (−0.44, p < 0.0001) and responsive to change in opinion postrandomization (−0.58, p < 0.0001). Baseline CLDEQ-8 scores by opinion status were as follows: Fair: 17.4 ± 8.7, Good 13.7 ± 6.4, Very Good 9.1 ± 4.7, and Excellent 6.4 ± 3.7 (ANOVA, F = 291.1, p < 0.0001). After 2 weeks, change in CLDEQ-8 scores by improvement status was as follows: Much Improved: −16.7 ± 10.0, Unchanged: −2.3 ± 5.0, to Much Worse +8.5 ± 5.8 (ANOVA, F = 16.5, p < 0.001).
Conclusions. The CLDEQ-8 score significantly reflected baseline status and change in overall opinion after refitting with two types of silicone hydrogels. The CLDEQ-8 score is a valid outcome measure in SCL clinical trials to reflect opinion of SCLs.
Although soft contact lenses (SCLs) have changed significantly over the past 10 years with the introduction of silicone hydrogel materials and newer designs, discontinuation of wear remains an important factor that limits the number of successful wearers.1,2 Ocular surface symptoms such as discomfort and dryness are most often reported as the chief cause of discontinuation for both hydrogel and silicone hydrogel lenses.2–4 In a cross-sectional survey of patients presenting for eyecare,4 >40% of former SCL wearers cited dryness as their primary reason to discontinue use of lenses, and this ranking has been confirmed in other recent studies.2
Dryness and discomfort with SCL use are very common. The prevalence of discomfort and dryness symptoms among SCL wearers is high, approximately 50%, which is at least double than that reported by subjects of similar age who were not using contact lenses.4,5 Even though so many SCL wearers report dryness and discomfort, there is no established level of symptoms that is considered clinically significant. Definitive diagnosis of SCL-related dryness remains a significant challenge, in part, because it is not a disease, per se, but is a symptomatic condition that is amenable to changes in SCL material6–8 or lens care products9,10 that can ameliorate symptoms. Finally, the SCL wearer may choose to cease lens wear altogether as a remedy for dryness symptoms.4
Recently the report from the 2007 Dry Eye Workshop included contact lens-related dry eye in the evaporative category.11 Soft contact lens wear is associated with reversible changes in corneal and conjunctival sensitivity and inflammation that may impact dryness symptoms.12–15 The potential to reverse SCL-related dryness creates a considerable need for a well-designed validated questionnaire for SCL-related dryness that is capable not only of assisting in diagnosis but also in measuring change in the condition that can be improved by available treatments. A number of questionnaires exist, but have not been validated so that the user knows the clinical meaning of scores or change in scores. A valid questionnaire should be able to identify SCL wearers who are struggling with clinically significant SCL-related dry eye complaints16 and be sensitive enough to track their progress when treated with products designed to reduce those symptoms.17,18
The Contact Lens Dry Eye Questionnaire (CLDEQ) was developed more than a decade ago to measure dryness symptoms among contact lens wearers.19,20 The CLDEQ instrument was originally designed in parallel to the Dry Eye Questionnaire (DEQ) for use in patients who do not wear contact lenses. The long forms of both the CLDEQ and DEQ instruments query contact lens-wearing history, frequency and diurnal intensity, and intrusiveness of nine ocular surface symptoms, along with questions about treatments, computer use, and environmental triggers. Recently, a validated five-item short form of the Dry Eye Questionnaire, the DEQ-5, was developed for patients who do not wear contact lenses.21 The DEQ-5 instrument uses a scoring system that is anchored by the patient's self-assessment of dry eye severity and contains five items. The purpose of this study was to develop and validate a short version of the CLDEQ for SCL wearers by identifying a set of questions that reflected satisfaction and overall opinion of SCLs that was also responsive to change among wearers of modern SCL materials.
The development of the short form of the CLDEQ was conducted in two phases. Both phases of this clinical research were conducted after institutional review board approval. All subjects signed informed consent before enrollment, and the studies were conducted in compliance with the Declaration of Helsinki and local Health Insurance Portability and Accountability Act guidelines.
This study took place in two phases, an item reduction phase and a known groups validity phase. Table 1 shows the lenses used in each phase of the research, although results were analyzed and displayed regardless of lens type. Subjects in both phases were included if they were at least 18 years old, if they needed bilateral correction, were in good general health, were willing and able to follow instructions, and were a current full-time and adapted wearer of SCLs. Subjects were not enrolled into the study if they were using monovision correction, were wearing rigid gas-permeable lenses, had clinically significant (grade 3 or 4) anterior segment abnormalities (or any iritis or any infection of the eye, lids, or adnexa), had ocular or systemic disease that would preclude SCL wear, or best-corrected Snellen visual acuity of <20/30 in either eye, or were pregnant or lactating females.
Item Reduction Phase
The purpose of the item reduction phase was to determine which symptoms and SCL-wearer coping mechanisms most highly correlated with the subjects' overall opinion of the SCLs at all study visits. This step was completed with data from a small study sample at the Indiana University School of Optometry. After signing consent documents, 38 (n = 38) frequent replacement SCL wearers completed a prospective randomized, cross-over SCL clinical trial that lasted for 4 weeks. Subjects were randomized at baseline to daily wear of either senofilcon A (Johnson & Johnson Vision Care, Inc, Jacksonville, FL) or balafilcon A (Bausch & Lomb, Rochester, NY) and then crossed over to the other lens at the 2-week visit (Table 1). All subjects were given OPTI-FREE EXPRESS MPDS (Alcon Laboratories, Ft. Worth, TX) with a screw-top lens case, and OPTI-FREE EXPRESS Rewetting Drops (Alcon Laboratories, Ft. Worth, TX) as needed.
At each visit (baseline, 1, and 2 weeks after each cross over for a total of five visits), responses to the long form of the CLDEQ were analyzed to identify items with the highest correlation to overall opinion of the SCLs at that visit (Poor, Fair, Good, Very Good, and Excellent). Groups of items that were most often highly correlated with overall opinion were tested in versions of the short form of the CLDEQ instrument after checking for redundant information (high inter-item correlation). Items with low correlations were not included in the combinations of questions that were tested. Items were removed in order of lower to higher correlation until there was no further impact on the analysis of variance (ANOVA) for the overall relationship to overall opinion of SCLs.
Known Groups Validity Phase
The purpose of the known groups validity phase was to validate the short CLDEQ-8—consisting of eight questions—by testing the sum scores for their ability to reflect overall opinion of habitual SCLs at baseline and for the score's responsiveness to change in overall opinion after randomization to two silicone hydrogel SCL materials. To accomplish this, the short form of the CLDEQ-8 was fielded to a much larger convenience sample in 24 North American clinical sites as part of a larger randomized prospective clinical trial. Subjects (n = 379) in an institutional review board-approved, multicenter, randomized parallel group trial completed the short form of the CLDEQ-8, and anchoring question on overall opinion of SCLs, and other questionnaires at baseline and 2 weeks after randomization to daily wear of either senofilcon A or lotrafilcon B silicone hydrogel lenses (Table 1). In this validation phase, subjects were allowed to continue to use their habitual care system (if appropriate) with the following distribution: OPTI-FREE RepleniSH 31%, ReNu MPDS 17%, OPTI-FREE EXPRESS MPDS 11%, and Clear Care 11%. Thirty percent (30%) of subjects were not using an appropriate care system (saline only or unknown system) and were given COMPLETE Multipurpose lens care kits at the baseline visit.
Change in overall opinion was measured by comparing the overall opinion rating (“Which statement best describes your overall opinion of your current contact lenses?” with response options of Poor, Fair, Good, Very Good, and Excellent) of habitual lenses to lenses to which the subject was randomized in the trial. For example, change in a worse direction would exist if the subject reported Very Good with habitual lenses and Good with new lenses. Change in assessment by two steps was considered “Much Worse” if it was in the worsening direction and “Much Better” if there were two levels of improvement in the overall opinion.
Only subjects with complete data sets (n = 309) were included in this analysis. Summed CLDEQ-8 scores (possible 0–37) were tested for correlation with overall opinion of habitual lenses (Spearman's rank correlation coefficient) and then for responsiveness to change in overall opinion after randomization by ANOVA. Statistical significance was assumed if p < 0.05.
Table 2 shows the demographics of the subject sample in each phase of the research and the distribution of habitual SCLs and care systems for subjects in each phase. Note that habitual lens care system was not queried in the item reduction phase of the research.
Item Reduction Phase
A number of CLDEQ questions were significantly correlated with overall opinion of contact lenses, with more questions showing significant correlations at visits after randomization than at baseline. Correlations between individual CLDEQ symptom questions at all visits are listed in Table 3.
Ranking of these correlations was used to model the best mix of questions for the short form of the CLDEQ. A strategy that chose questions with the highest correlations and highest proportions of significant correlations was put into a sequence that was then tested to reduce redundancy. Some questions, such as burning/stinging, showed very high statistically significant correlations with other items that also had high correlation to overall opinion. Those questions were eliminated from the final CLDEQ-8 short form, as they did not affect the overall performance of the instrument's ability to discriminate by the wearer's overall opinion of the SCLs they were wearing at that visit. The CLDEQ-8 questions are shown in Fig. 1.
Known Groups Validity Phase
Fig. 2 shows the mean and distribution of CLDEQ-8 scores by overall opinion of habitual lenses at baseline for the known groups validity phase. The distribution of CLDEQ-8 scores by overall opinion of lenses was as follows: Fair: 17.4 ± 8.7, Good: 13.7 ± 6.4, Very Good: 9.1 ± 4.7, and Excellent: 6.4 ± 3.7, and the overall distribution was significant (ANOVA, F = 291.1, p < 0.001). There were no subjects who reported Poor overall opinion at baseline.
The distribution of change in overall opinion by change in CLDEQ-8 score is shown in Fig. 3. Note that a lower CLDEQ-8 score indicates fewer symptoms and less need for coping actions. In general, the 73 subjects who reported a worse overall opinion status had an 8.5 ± 5.8 point increase in the CLDEQ-8, the 218 in the unchanged group had a decrease of −2.3 ± 5.0 points, and the 11 subjects with improved status had a change of −16.7 ± 10.0 points in CLDEQ-8 scores. The distribution was significantly related to change in overall opinion of SCLs (ANOVA, F = 16.5, p < 0.001).
Although numerous questionnaires have been developed to assess dry eye symptoms without contact lens use,22–25 and others to assess quality of life across refractive correction,25–29 the CLDEQ is one that was developed to assess dry eye symptoms among contact lens wearers in particular. A population-specific SCL questionnaire is required because SCL wearers report a distinctly different pattern of symptoms compared with people who do not wear SCLs.16 For example, in an age-matched sample of SCL wearers and non-wearers, more than twice as many SCL wearers reported intense dryness, especially late in the day, but these symptoms were nearly eliminated when they removed lenses.4 In that study, symptom patterns also differed between SCL wearers and age-matched non-wearers; in SCL wearers, dryness intensity was not correlated with gender although it was inversely correlated with age among contact lens wearers, differing significantly from the pattern among non-lens wearers in which females and older patients report more dryness.
Because SCL-related dryness is not a disease, we developed a responsive tool to measure its recovery. The CLDEQ-8 was able to reflect improvement and worsening of overall opinion after randomization to new lenses. The SCL wearer's opinion can change after refitting with new lens designs, materials, lens care products, and with new replacement schedules; thus, the score to reflect that opinion should be developed by methods that sample patients' symptoms during the refitting process.
The CLDEQ-8 is a short form of the CLDEQ questionnaire that was designed to describe symptoms among SCL wearers. The short form was developed by selecting items that related to the wearer's global opinion of the SCLs they were wearing across all study visits. The number of items was then reduced to avoid redundancy owing to very high inter-item correlation. The eight remaining items were also capable of reflecting change in this opinion after randomization to new lens brands in the second phase of the study. Scores from an earlier short CLDEQ version relied on the response to the question “Do you think you have dry eye?,” which was useful as a stratifying question in dry eye patients without SCL wear.30 Reliance on the Gestalt “Do you think you have dry eye?” question may not be a good approach with SCL wearers, as many of them have few symptoms while not wearing lenses.4 Therefore, SCL wearers with dry eye complaints may not globally consider themselves to have dry eye separately from SCL wear. The overall opinion question used in this study focuses on the SCLs and not on the patient's underlying condition of eye dryness. In addition, the earlier short CLDEQ formula was less intuitive and possibly more cumbersome for clinician users to implement.
The CLDEQ-8 score shows an excellent dose–response relationship to the subjects' overall opinion of SCLs, making it a potentially useful tool for capturing the patient-reported opinion of new SCL treatments. There was a slight dampening of linearity in the scale when we related it to change in opinion after refitting with new lenses. Subjects showed larger change in score when they reported an improvement in overall opinion (mean decrease of 16.7 points) compared with when they had a lower overall opinion of the new lenses (mean increase of 8.5 points). Other researchers have shown that the structure of the DEQ questions showed linearity by Rasch analysis.31 In this sample, we were unable to assess the lowest end of the scale, as none of the subjects presenting for the clinical trial had an estimation of “Poor” for their habitual SCLs. Contact lens-related dryness differs from dry eye disease (fortunately for the lens wearers) in that the patient is able to cease wear if the lenses are so uncomfortable that they would warrant a poor rating. Inability to test that end of the scale is a limitation in the development of the instrument. Repeatability of the instrument should also be established in other patient populations in the future.
For diagnostic use and categorization, a valid and useful instrument must be able to distinguish between groups that are otherwise identifying themselves as different, a feature referred to as having construct validity. The items in the CLDEQ-8 were selected from the ocular surface symptoms, environmental triggers, and coping items in the longer CLDEQ questionnaire. Also, the selection was based on patient opinion of SCLs after changes between marketed lens brands, so the CLDEQ-8 is scaled to perform well to reflect changes of a magnitude that are clinically achievable through change in available products.
Ideally, we would like to understand the underlying biological basis of SCL-related dryness symptoms and have means of measuring those specific factors. However, with or without that basic understanding, a gold standard, or highly repeatable clinical tests, it remains important to be able to measure symptoms as assessed by individual SCL wearers in the clinical or clinical trial setting. The CLDEQ-8 allows a standardized quick means to measure this symptom-based condition from the wearer's point of view. Note that two vision (frequency and late day intensity) and two coping (removing lenses early and closing eyes for relief) questions are included in the CLDEQ-8 but were not the most discriminating questions in the short form of the DEQ-5.21 With SCL wear, the prelens tear film is significantly less stable with SCLs compared with the precorneal tear film in patients without SCLs32,33; therefore, changeable blurry vision has been cited as a more prominent symptom in the SCL population. Blurry vision that clears with a blink is the third most common symptom among SCL wearers, close behind discomfort and dryness. This complaint of transient blurry vision most likely stems from the tear break up that occurs between blinks in SCL wearers.34 This recent study of blinking patterns during different cognitive tasks with and without SCL wear showed that the unstable prelens tear film, and symptoms associated with it, drove an increase in blink frequency during SCL wear compared with no wear.
The two coping questions included in the CLDEQ-8, the need to close the eyes and early lens removal, capture the wearer's struggle with uncomfortable lenses. Subjects in this study with lowest overall opinion of SCLs were more likely to frequently close their eyes for a prolonged time or to finally capitulate and remove lenses before the desired time. It is clear that these symptoms alter the SCL-wearing experience and reflect a significant impact on the wearers who experience them.
In this study, we validated the eight-item short form of the CLDEQ as a means of testing the SCL wearer's symptom-related experience with their contact lenses. The sum of scores for the eight items was significantly related to overall opinion of lenses and was also able to reflect change in overall opinion in prospective treatment trials. The CLDEQ-8 will be useful for identification of SCL wearers who may benefit from lenses or lens care products designed to reduce symptoms of dryness with SCL wear and to track their progress in treatment trials.
Robin L. Chalmers
Clinical Trial Consultant
2097 East Lake Road
Atlanta, Georgia 30307
This study was funded by Johnson & Johnson Vision Care, Inc., and designed by RLC, CGB, and KM. We thank Graeme Young, PhD, MPhil, FCOptom, DipCL, FAAO, and Chris Hunt, MSc, and the staff at Visioncare Research for their assistance in fielding the CLDEQ-8 in the Known Groups Validity Phase.
1. Doughty MJ, Fonn D, Richter D, Simpson T, Caffery B, Gordon K. A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada. Optom Vis Sci 1997;74:624–31.
2. Richdale K, Sinnott LT, Skadahl E, Nichols JJ. Frequency of and factors associated with contact lens dissatisfaction and discontinuation. Cornea 2007;26:168–74.
3. Young G, Veys J, Pritchard N, Coleman S. A multi-centre study of lapsed contact lens wearers. Ophthalmic Physiol Opt 2002;22:516–27.
4. Chalmers RL, Begley CG. Dryness symptoms among an unselected clinical population with and without contact lens wear. Cont Lens Anterior Eye 2006;29:25–30.
5. Guillon M, Maissa C. Dry eye symptomatology of soft contact lens wearers and nonwearers. Optom Vis Sci 2005;82:829–34.
6. Riley C, Chalmers RL, Pence N. The impact of lens choice in the relief of contact lens related symptoms and ocular surface findings. Cont Lens Anterior Eye 2005;28:13–9.
7. Riley C, Young G, Chalmers R. Prevalence of ocular surface symptoms, signs, and uncomfortable hours of wear in contact lens wearers: the effect of refitting with daily-wear silicone hydrogel lenses (senofilcon a). Eye Contact Lens 2006;32:281–6.
8. Chalmers R, Long B, Dillehay S, Begley C. Improving contact-lens related dryness symptoms with silicone hydrogel lenses. Optom Vis Sci 2008;85:778–84.
9. Stiegemeier MJ, Friederichs GJ, Hughes JL, Larsen S, Movic W, Potter WB. Clinical evaluation of a new multi-purpose disinfecting solution in symptomatic contact lens wearers. Cont Lens Anterior Eye 2006;29:143–51.
10. Lebow KA, Schachet JL. Evaluation of corneal staining and patient preference with use of three multi-purpose solutions and two brands of soft contact lenses. Eye Contact Lens 2003;29:213–20.
11. Lemp M, Baudouin C, Baum J, Dogru M, Foulks GN, Kinoshita S, Laibson P, McCulley J, Murube J, Pfugfelder SC, Rolando M, Toda I. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:75–92.
12. Situ P, Simpson TL, Jones LW, Fonn D. Effects of silicone hydrogel contact lens wear on ocular surface sensitivity to tactile, pneumatic mechanical, and chemical stimulation. Invest Ophthalmol Vis Sci 2010;51:6111–7.
13. Liu Q, McDermott AM, Miller WL. Elevated nerve growth factor in dry eye associated with established contact lens wear. Eye Contact Lens 2009;35:232–7.
14. Dogru M, Ward SK, Wakamatsu T, Ibrahim O, Schnider C, Kojima T, Matsumoto Y, Ogawa J, Shimazaki J, Tsubota K. The effects of 2 week senofilcon-A silicone hydrogel contact lens daily wear on tear functions and ocular surface health status. Cont Lens Anterior Eye 2011;34:77–82.
15. Schultz CL, Kunert KS. Interleukin-6 levels in tears of contact lens wearers. J Interferon Cytokine Res 2000;20:309–10.
16. Chalmers RL, Hunt C, Hickson-Curran S, Young G. Struggle with hydrogel CL wear increases with age in young adults. Cont Lens Anterior Eye 2009;32:113–9.
17. Schafer J, Mitchell GL, Chalmers RL, Long B, Dillehay S, Barr J, Bergenske P, Donshik P, Secor G, Yoakum J. The stability of dryness symptoms after refitting with silicone hydrogel contact lenses over 3 years. Eye Contact Lens 2007;33:247–52.
18. Young G, Riley CM, Chalmers RL, Hunt C. Hydrogel lens comfort in challenging environments and the effect of refitting with silicone hydrogel lenses. Optom Vis Sci 2007;84:302–8.
19. Begley CG, Caffery B, Nichols KK, Chalmers R. Responses of contact lens wearers to a dry eye survey. Optom Vis Sci 2000;77:40–6.
20. Begley CG, Chalmers RL, Mitchell GL, Nichols KK, Caffery B, Simpson T, DuToit R, Portello J, Davis L. Characterization of ocular surface symptoms from optometric practices in North America. Cornea 2001;20:610–8.
21. Chalmers RL, Begley CG, Caffery B. Validation of the 5-Item Dry Eye Questionnaire (DEQ-5): discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses. Cont Lens Anterior Eye 2010;33:55–60.
22. Fairchild CJ, Chalmers RL, Begley CG. Clinically important difference in dry eye: change in IDEEL-symptom bother. Optom Vis Sci 2008;85:699–707.
23. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 2000;118:615–21.
24. McMonnies CW, Ho A. Responses to a dry eye questionnaire from a normal population. J Am Optom Assoc 1987;58:588–91.
25. Abetz L, Rajagopalan K, Mertzanis P, Begley C, Barnes R, Chalmers R. Development and validation of the impact of dry eye on everyday life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients. Health Qual Life Outcomes 2011;9:111.
26. Vitale S, Schein OD, Meinert CL, Steinberg EP. The refractive status and vision profile: a questionnaire to measure vision-related quality of life in persons with refractive error. Ophthalmology 2000;107:1529–39.
27. Hays RD, Mangione CM, Ellwein L, Lindblad AS, Spritzer KL, McDonnell PJ. Psychometric properties of the National Eye Institute-Refractive Error Quality of Life instrument. Ophthalmology 2003;110:2292–301.
28. Pesudovs K, Garamendi E, Elliott DB. The Quality of Life Impact of Refractive Correction (QIRC) Questionnaire: development and validation. Optom Vis Sci 2004;81:769–77.
29. Pesudovs K, Garamendi E, Elliott DB. The Contact Lens Impact on Quality of Life (CLIQ) Questionnaire: development and validation. Invest Ophthalmol Vis Sci 2006;47:2789–96.
30. Nichols JJ, Mitchell GL, Nichols KK, Chalmers R, Begley C. The performance of the contact lens dry eye questionnaire as a screening survey for contact lens-related dry eye. Cornea 2002;21:469–75.
31. Simpson TL, Situ P, Jones LW, Fonn D. Dry eye symptoms assessed by four questionnaires. Optom Vis Sci 2008;85:692–9.
32. Glasson MJ, Stapleton F, Keay L, Sweeney D, Willcox MD. Differences in clinical parameters and tear film of tolerant and intolerant contact lens wearers. Invest Ophthalmol Vis Sci 2003;44:5116–24.
33. Guillon M, Styles E, Guillon JP, Maissa C. Preocular tear film characteristics of nonwearers and soft contact lens wearers. Optom Vis Sci 1997;74:273–9.
34. Jansen ME, Begley CG, Himebaugh NH, Port NL. Effect of contact lens wear and a near task on tear film break-up. Optom Vis Sci 2010;87:350–7.
soft contact lens; symptoms; dryness; questionnaire; Contact Lens Dry Eye Questionnaire; CLDEQ
© 2012 American Academy of Optometry
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Highlight selected keywords in the article text.
Data is temporarily unavailable. Please try again soon.